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Summary  
Vaccines against human breast cancer are an unfulfilled promise. 
Despite decades of promising preclinical and clinical research, no vaccine is 
currently available for breast cancer patients. Preclinical research has much to 
do with this failure, because early mouse models of mammary carcinoma did 
not mirror the molecular, cellular, antigenic and immunological features of 
human breast cancer. The advent of HER-2 transgenic mice gave impulse to a 
new generation of cell and DNA vaccines against mammary carcinoma, that 
in turn led to the definition of significant antigenic (oncoantigens) and cellular 
(cancer-initiating cells, preneoplastic lesions, incipient metastases) targets. 
Future preclinical developments will include the discovery of novel 
oncoantigens in HER-2-negative mammary carcinoma and the targeting of 
activated HER-2 molecular variants. Translation to clinically effective vaccines 
will be fostered not only by new preclinical model systems, but also by the 
possibility to conduct veterinary vaccination trials in companion animals. 
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Preclinical models of mammary carcinoma for tumor immunology 
Research on mammary carcinoma is inextricably interwoven with the 
history of preclinical models, starting with the development in the 1920s of 
the C3H mouse strain, selected for a high incidence of mammary tumors. It is 
a history that illustrates very well some critical issues of preclinical models in 
general[1]. On the one side, the C3H model of mammary carcinoma, caused 
by the mouse mammary tumor virus (MMTV), is no longer regarded as a 
reliable model for human breast cancer, which is not caused by viruses. On 
the other side, the discovery of MMTV and the analysis of its oncogenic 
activity were key steps in the development of molecular oncology, eventually 
leading to the discovery of various oncogenes.Today MMTV continues to 
contribute to mammary carcinoma preclinical models, because its (relative) 
tissue specificity was harnessed to drive the expression of oncogenes and 
other genes in the mammary gland, and many transgenic mice prone to 
mammary carcinoma in use today were designed using (non-coding) MMTV 
sequences[2]. 
 
Cell lines 
In addition to the viral etiology, MMTV-infected mice have 
shortcomings as model systems for vaccination studies. Obviously viral 
antigens are expected to dominate or otherwise distort the immune responses 
elicited by vaccines, a further difference with human breast cancer. 
Furthermore, tumor onset and growth required repeated pregnancies and 
lactation, altogether making MMTV-infected mice a poorly reproducible and 
cumbersome system for immunological studies[1]. Starting in the 1970s, 
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immunological research resorted to the use of cell lines derived from 
mammary carcinomas, for example from occasional spontaneous carcinomas, 
arising in “retired breeders”, i.e. old multiparous females, of MMTV-free 
strains, like BALB/c[3]. These cell lines were thought to reproduce the low 
immunogenicity of human tumors, thus giving rise to more faithful 
preclinical models for vaccination studies. While it is true that cell lines like 
TS/A were poorly immunogenic, in retrospect they were not exempt from the 
“viral sin”, because in many instances the immunodominant antigens were 
later shown by molecular studies to be related to endogenous retroviral 
sequences [4,5]. 
 
Genetically modified mice 
The advent of genetically modified mice has revolutionized biomedical 
research, allowing the establishment of preclinical models of human diseases 
for which no equivalent spontaneous mouse pathology existed or was not a 
faithful model of human disease, as is the case of mammary carcinoma. 
Immunological studies focused on HER-2 transgenic mice, that offered 
for the first time a preclinical model of high penetrance mammary 
carcinogenesis caused by an oncogene known to be involved in human breast 
cancer, and at the same time offered an attractive immunological target. Many 
different HER-2 transgenic mouse lines were produced over the last 25 
years[6] thus it is important to understand their characteristics in relation to 
human breast cancer[7]. Under this respect it should be noted also that our 
knowledge of human tumors has evolved in parallel, leading to different 
perceptions of what can be considered a good animal model. Think for 
example of point mutations, which for many years were thought to be almost 
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non-existent in human pathology, whereas next generation sequencing is 
bringing to light a small but consistent percentage of tumors driven by 
mutant HER-2[8]. 
Earlier transgenic mice carried a mutant rat HER-2 (the HER-2 oncogene 
was originally cloned in rat and called neu) transgene controlled by MMTV 
long terminal repeat (LTR) sequences [2,9] and displayed a very aggressive 
mammary carcinogenesis, with progressive carcinomas in all ten mammary 
glands within the first semester of life. The same promoter was then used to 
drive the wild-type (i.e. non-mutated) rat HER-2 gene in atransgenic model 
with a milder carcinogenesis, displaying carcinomas in 2-4 mammary glands 
by one year of age[10]. 
The following step was the replacement of the rat oncogene with the 
human ortholog, thus obtaining a transgenic mouse in which anti-human 
HER-2 antibodies and analogous therapeutic agents could be directly 
tested[11].Latest developments were driven by the discovery in humans of 
activated HER-2 variants, such as the Delta16 isoform or the p95 truncation, 
that were shown to be highly oncogenic in transgenic mice, ultimately giving 
rise to novel model systems that reproduce the aggressiveness of those based 
on the mutant rat oncogene[12-14]. 
Widespread interest in these transgenic models of mammary 
carcinogenesis led to the developments of countless mouse lines of different 
genetic backgrounds, bearing different oncogenes, different promoters, and 
combinations of HER-2 with many other cancer genes[6,7]. We will restrict 
ourselves to some basic key elements based on our experience for the choice 
of a system for preclinical vaccine studies. 
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1. Tumor penetrance is the first element. Many interesting transgenic 
lines with a low tumor incidence make extremely cumbersome 
model systems and mandate the use of very large experimental 
groups. Whenever possible prefer models with a nearly 100% 
incidence. 
2. Tumor latency is another key. Experiments in transgenic mice take a 
long time in comparison to those with transplanted cell lines, and if 
your vaccine effectively prevents tumors you will need even longer 
observation times. Models in which the first tumors appear after one 
year of age make the life hard for a successful vaccinologist. Apart 
from practical considerations, it should be also kept in mind that a 
long tumor latency in a mouse carrying an oncogene means that 
additional genetic events are required for tumor onset, which could 
be either an advantage or a disadvantage, depending on the type of 
research project. 
3. Aggressiveness is not to be feared. When we started the study of 
anti-HER-2 preventive vaccines, we thought that a mouse prone to 
the onset of invasive carcinomas in all mammary glands was a 
daunting prospect, however our experience showed that powerful 
vaccines could completely prevent tumor onset in these mice[15,16], 
provided that vaccinations started at the right time[17], which brings 
us to the following point. 
4. Timing is of the essence. As transgenic mice reproduce tumor 
progression, the effectiveness of cancer vaccines is frequently 
dependent on vaccination schedules taylored on the stages of tumor 
progression (e.g. atypical hyperplasia,  in situ carcinoma, angiogenic 
switch, wtc.) in the model in use. Fortunately, a key advantage of 
transgenic models of mammary carcinogenesis is the repeatability 
(with possible variations) of tumor progression. 
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Human-in-mouse systems 
Until recently, the only way to investigate human immune responses to 
vaccines, short of actually immunize human subjects, was the in vitro study of 
immune cell reactivity, clearly a suboptimal way to investigate the 
complexities of in vivo responses. Paradoxically, the advent of highly 
immunodeficient mouse models has considerably improved not only the 
study of human tumor biology, but also that of human immunology[18]. 
Residual immune responses, in particular NK cells, of older immunodeficient 
mouse models, such as athymic nude mice, considerably impair the survival 
of implanted human cells, both normal and neoplastic[19,20]. 
A key development was the knockout of the common gamma subunit of 
interleukin receptors (Il2rg), that blocks NK development. Mouse models 
combining T and B cells deficiencies with Il2rg knockout, such asRag2-/-;Il2rg-/- 
(BRG) or NOD-scid-gamma (NOG) mice, allow for the first time the study of 
HER-2+ human breast cancer dissemination, and at the same time can be 
reconstituted with human stem cells that give rise to a functional immune 
system[21]. We have recently shown that, in reconstituted BRG mice, the 
human immune system can respond to vaccines against human HER-2 with 
the production of specific antibodies and possibly other immune responses 
that hamper the metastatic spread of human tumor cells[22]. 
At present the study of vaccines in mice with a reconstituted immune 
system has various shortcomings, for example human immune responses are 
clearly suboptimal and incompletely developed. Furthermore, the use of cord 
blood as the major source of human stem cells rules out the study of 
autologous immune responses for adult tumors. Current studies clearly show 
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how far the knockout of just one gene has opened new avenues in preclinical 
models, thus, even if current models are still imperfect, further improvements 
are expected to lead to the development of fully human preclinical models for 
cancer vaccines. 
 
Natural occurring cancers in pet animals 
In 2003, the National Cancer Institute's Center for Cancer Research 
(CCR) launched the Comparative Oncology Program (COP) 
(https://ccrod.cancer.gov/confluence/display/CCRCOPWeb/Home) to foster 
the use of naturally occurring cancer in pet animals - primarily dogs and cats 
– as models of human cancer [23]. Generally, pet’s and human tumors have 
many similarities, including histological appearance, tumor genetics, 
molecular targets, biological behavior and response to conventional therapies. 
Moreover, being dogs and cats the favored companions of humans, they share 
the same environmental exposure to risk factors. Moreover, inclusion of dogs 
or cats from different breeds in clinical trials provides a cross-sectional value 
that is often higher than that obtained in studies of inbred laboratory animals, 
by providing a background genetic diversity similar to that seen in human 
populations. Noteworthy, the first licensed therapeutic vaccine for the 
treatment of cancer (ONCEPTTM, Merial) is a xenogeneic DNA vaccine against 
human tyrosinase recently approved for veterinary use against canine 
malignant melanoma [24], whose initial testing in dogs [25-27] led to its use in 
human trials [28-30]. 
Both canine and feline mammary carcinomas can be used to study 
different aspects of human breast cancer. The percentage of malignant 
mammary tumors is higher in cats than in dogs. While dogs are considered a 
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good model of human inflammatory breast cancer, feline mammary 
carcinoma has been proposed as a model for poor prognosis human breast 
cancer. Feline mammary cancer is similar to human breast cancer in the age of 
onset, incidence, histopathologic features, biologic behavior, and pattern of 
metastasis [31]. In particular, HER-2 overexpressing feline mammary 
carcinoma is very similar to the human counterpart [32]. Testing of DNA 
vaccination against HER-2 in cats is ongoing (Dr. Wei-Zen Wei, Karmanos 
Cancer Center, Detroit, USA; personal communication). 
Will the pet lead to a breakthrough in the fight against cancer? The 
premises are good, but there is still much work to do. 
 
Vaccination strategies and protective immune responses 
Vaccines for immunoprevention of mammarycarcinoma  
Studies of mammary carcinoma preventive vaccines in HER-2 
transgenic mice not only contributed to the notion of non-viral cancer 
immunoprevention, but also highlighted various important concepts in tumor 
immunology. We have reviewed this field in the recent past[33-35],therefore 
here we will focus on general principles relevant to vaccine development, 
summarizing the most important conclusions. 
Effective vaccines were able to completely block the development of 
mammary carcinoma in HER-2 transgenic mice[15,16,36]. Different vaccine 
formulations, such as cell-based and DNA vaccines were equally effective[37]. 
Common vaccinological properties were the use of powerful adjuvants and 
intensive vaccination schedules. Microscopic analysis revealed that cancer 
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progression was indefinitely “frozen” at the stage of hyperplasia by 
vaccination, and that HER-2 expression was greatly down modulated[38]. 
Immunological studies showed that protective immune responses 
elicited by vaccines were mainly based on helper T cell cytokines, in 
particular gamma interferon, and anti-HER-2 antibodies of Th1 isotypes (like 
IgG2a and IgG2b in the mouse), whereas cytotoxic T cell responses did not 
play a relevant role[39]. Antibodies were the effectors of long-term protection, 
and titers after the first cycles of vaccination predicted long-term protection 
from tumor development[37]. 
 
Therapeutic vaccines 
Basically most preclinical vaccination experiments targeted “local” 
mammary carcinomas. Countless experiments were performed over the years 
using almost any conceivable vaccine design and formulation, and the 
ensuing publications attest the attainment of several positive results with 
many different vaccination approaches[40]. A comprehensive review would 
be at once humongous and useless. We would rather provide a critical 
appraisal of some key issues related to preclinical models, because the 
continuing lack of clinical impact vis-à-vis the huge amount of positive 
preclinical results could suggest that past and current preclinical models are 
part of the problem. 
The first thing to stress is that the model system used for preclinical 
testing is an important variable, and that there are innumerable variations 
that can directly impact the results. In general one must ask up front how far 
removed from the human condition is the preclinical model. The trade-off is 
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between “simple” models that are quite different from clinical situations and 
cumbersome systems that more closely mirror human pathology and therapy. 
The simplest thing to do is to perform a classical vaccination-challenge 
experiment: tumor-free mice are first vaccinated, and then challenged 
subcutaneously with a syngeneic mammary carcinoma cell line. At the 
opposite end of the spectrum is therapeutic vaccination administered to a 
mouse bearing a spontaneous (“autochthonous”) mammary carcinoma or, 
even better, the same mouse undergoing surgical removal of the 
primarytumor followed by therapeutic vaccination for prevention or therapy 
of distant metastases[41]. 
Being guilty of using, over the years, practically every variation of 
preclinical models for studying mammary carcinoma vaccines, we can only 
practice non-directive counselling. 
1. Vaccination-challenge experiments are fine to demonstrate 
principles, but to start a translational approach, a therapeutic set-up, 
in which vaccines are administered to tumor-bearing mice, would be 
more realistic. 
2. Orthotopic injection of mammary carcinoma is easy. It is well known 
that growing tumors in the appropriate anatomic site better 
reproduces human pathophysiology, and injection of mammary 
carcinoma cells in the mammary fat pad is not difficult, in 
comparison to the problems posed by other tumor types (think for 
example of glioblastoma). 
3. Metastases are better targets than local tumors. It is quite obvious 
that preclinical vaccine therapy of local tumors is mostly devoid of 
translational meaning, because human patients succumb to 
metastases after surgical removal of the primary tumor. A less 
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appreciated advantage of preclinical models of metastasis therapy is 
that metastasis evaluation(by direct count of through imaging 
techniques) is a highly sensitive and exquisitely quantitative 
endpoint, superior to volumetric measurements of local tumors. It 
must be kept in mind that the cure of micrometastasis is at the 
boundary between prevention and therapy[42]. Metastatic cells 
newly arrived in a distant organ face much of the hurdles of early 
neoplastic cells, and are more sensitive to immunotherapies than 
established tumor masses. In HER-2 transgenic mice we found that 
the efficacy of an anti-HER-2 vaccine followed a saddle-like curve 
related to tumor development and progression[35]. Maximal efficacy 
was obtained in preventive protocols starting before tumor onset, 
followed by a precipitous loss of activity against established 
tumors[17,36]. However the same vaccine was again active against 
metastasis development, demonstrating that preventive oncologists 
are right when they designate as “tertiary cancer prevention” what 
medical oncologists call adjuvant therapy[43]. 
4. Transgenic models of mammary carcinogenesis can be unsuitable for 
studies of autochthonous metastases[42]. Aggressive mammary 
carcinogenesis, in some cases leading to the continuing development 
of independent carcinomas in all mammary glands, can prevent 
meaningful studies of metastasis therapy in the absence of growing 
primary tumors. 
5. Studying naturally occurring tumors in pets is likely to provide a 
valuable perspective that is distinct from that generated by studying 
rodent models alone before first in-human studies[44]. An increasing 
number of trials is ongoing in various Veterinary Teaching Hospitals, 
both in Europe and in the USA, and promise to solve many problems 
of mouse pre-clinical models. 
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Targeting of cancer stem cells 
To date, bulk tumor masses with heterogeneous populations of cancer 
cells have been used as a source of potential drug or vaccination targets. 
However, human tumors are composed of heterogeneous cancer cell sub-
populations that differ with respect to proliferation, differentiation, and 
ability to initiate daughter tumors. The slowly dividing cancer initiating cells 
endowed with stem cell properties, like the capacity to self-renew and to 
reestablish tumor heterogeneity, appear to be the sub-population responsible 
for tumor progression, metastatization, resistance to therapy, and tumor 
recurrence [45]. 
The notion that cancer stem cells may play a major role in cancer 
progression has important implications. It may account for most of the 
difficulties of current treatments in eradicating malignant tumors. Those 
treatments designed to shrink the bulk of a tumor may fail to eliminate the 
small fraction of cancer stem cells endowed with chemo- and radio-resistance 
and immune-evasive features [46]. In some cases, the vaccine-induced 
response against antigens identified in the bulk of the tumor, may even drive 
the selection of cancer stem cells and promote tumor growth [47]. Instead, for 
therapy to be more effective, debulking of differentiated tumors must occur 
followed by targeting of the remaining surviving often quiescent cancer stem 
cells. A recent report actually demonstrated that a vaccine done of dendritic 
cells primed with antigens derived from purified cancer stem cells induced a 
significant protective antitumor immunity in mouse models [48].  
The understanding of the pathways regulating breast cancer stem cell 
self-renewal, differentiation and tumorigenicity, and the identification of 
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appropriate drug and vaccination targets may be critical in the development 
of effective breast cancer therapies[49]. 
 
Target antigens 
HER-2 is a superior target for mammary carcinoma immunotherapy, 
both in humans and in preclinical models. Why? In other words, is HER-2 
endowed with specific features not shared by other tumor antigens? And can 
we derive general principles that will help in defining novel tumor antigens 
on a par with HER-2? 
On the experience of cancer immunoprevention in HER-2 transgenic 
mice, we defined two key antigenic features of HER-2. Firstly, HER-2 was at 
the same time the driving oncogene of mammary carcinogenesis and the 
target antigen. In our model systems, HER-2 was necessary for tumor onset, 
and cell variants with low/absent HER-2 expression (observed only in vitro) 
displayed a simultaneous loss of tumorigenicity[50]. Secondly, down-
modulation of class I major histocompatibility complex glycoproteins, an 
overly common human tumor phenotype[51], was observed also in vivo in 
mammary carcinomas of HER-2 transgenic mice, indicating that T cell 
recognition of tumor cells could be severely hampered[52].However, surface 
expression of HER-2 preserved immune recognition by antibodies, which in 
fact were the main immune effectors of protection from tumor onset[39]. 
In other words, HER-2 is a good antigen because it is impervious to the 
two main causes of immunotherapeutic failure, antigen loss and MHC loss. A 
generalization of these concepts lead to the definition of a novel category of 
tumor antigens, that we named oncoantigens. 
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Oncoantigens 
In the original definition, we called oncoantigens those tumor antigens 
that play a causal role in tumor development and are expressed on the cell 
surface[33]. More recently we revised the original definition to include further 
categories of promising antigenic targets having in common an oncogenic 
role[34,35]. 
Class Ioncoantigens coincide with the original definition. The prototypic 
class I oncoantigen is HER-2, accompanied by receptor tyrosine kinases and 
many other surface molecules that are indispensable for tumor and metastasis 
development 
Class IIoncoantigens include soluble antigenic targets that promote 
tumor growth directly, for example growth factors, or indirectly, for example 
angiogenic factors. 
Class III oncoantigensare intracellular molecules controlling tumor 
growth. 
In essence the oncoantigen concept affirms that molecules driving 
cancer are more persistent antigenic targets than “passenger” molecular 
alterations. Cancer progression and selective pressure exerted by therapeutic 
agents can result in a succession of different drivers over time, therefore the 
persistence of oncoantigens is to be understood in relative, not absolute terms. 
However there will always be driving molecules to be targeted in a given 
stage of tumor development. 
From an immunological perspective, the three classes define a 
hierarchy of effector mechanisms, because class Ioncoantigens (membrane) 
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are targeted both by T cells and by antibodies, class II molecules (soluble) are 
only bound by antibodies, while class III (intracellular) can be recognized only 
by T cells in association with MHC molecules. Given the widespread of MHC 
loss in tumors [53,54], broadly speaking class I (and II) oncoantigens are  more 
attractive, however also class III oncoantigens have been successfully targeted 
[55,56], and a possible role of antibodies even against these oncoantigens 
hiddeninside the cell has been recently hypothesized[57,58]. 
 
Discovery of novel oncoantigens – Preneoplastic lesions, differentiated tumor cells, 
cancer stem cells 
The most important oncoantigen identified so far for breast cancer is 
HER-2, and the development of innovative therapeutic options that 
specifically target HER-2 or other members of the HER family has represented 
one of the most important achievement in clinical oncology. Similarly, many 
vaccination strategies against HER-2 have been successfully developed in pre-
clinical models and are now under clinical investigation. Nevertheless, only 
20-30% of mammary cancers overexpress HER-2; moreover, a prolonged 
exposition of HER-2 overexpressing tumors to anti-HER-2 treatments, both 
with antibodies or tyrosine kinase inhibitors, often results in the development 
of HER-2-negative, therapy-resistant variants [59]. Identification of additional 
oncoantigens for immune targeting of mammary cancer is thus needed. 
Microarray transcription studies are a powerful instrument to identify 
potential oncoantigens on a genome-wide basis. We have generated a pipeline 
for oncoantigen identification based on the integration of gene expression 
data from mammary cancer-prone genetically engineered mice and human 
mammary cancer [60]. Mammary tissue samples are collected from mice of 
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various ages, corresponding to different stages of tumor progression, from 
atypical hyperplasia to invasive cancer; total RNA is extracted and gene 
expression profiles are generated using genome-wide mouse arrays. Of the 
transcripts up-regulated going from pre-neoplastic lesions to overt cancer, 
only those that have an orthologue in humans, low expression in normal 
human tissues, and a high and homogeneous expression in human cancers 
are selected. The functional role of the corresponding molecules in fostering 
the transformed phenotype is investigated. Vaccines against these “putative” 
oncoantigens are then generated to immunize cancer-prone transgenic mice 
and assess whether an effective immune response affecting tumor progression 
can be generated[61].In this way several oncoantigens have been identified 
[34,61]. Additional oncoantigens generated by specific mRNA isoform usage 
or represented by aberrant fusion products can now be identified using Next 
Generation Sequencing technology. 
This approach allows the identification of oncoantigens expressed by 
the bulk of differentiated tumor cells, and by any other cell population in the 
tumor microenvironment (infiltrating cells, tumor stromal and endothelial 
cells) whose number increases with tumor progression. On the other hand, it 
does not allow the identification of the oncoantigens specifically expressed by 
CSC, whose relative number in the bulk of the tumor cells remains very low.  
The surface marker phenotypes of the CSC from different mammary 
cancer sub-types are still the subject of some debate since significant 
differences in marker expression within the same sub-type are evident. For 
this reason CSC isolation on the basis of surface markers alone is quite 
controversial. Mammary CSC down-regulate cell-cell junctions, display 
mesenchymal behavior in vitro, and survive and proliferate in anchorage-
independent conditions in the form of floating spherical colonies termed 
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mammospheres [62,63]. CSC from human and mouse mammary tumor 
specimens, metastases, and cell lines can therefore be isolated in function of 
their ability to grow as non-adherent spheres [63]. These mammospheres 
express markers associated with the CSC phenotype, and are able to 
efficiently generate tumors when injected into syngeneic (murine CSC) or 
immunodeficient (human CSC) mice.  By comparing the transcription profile 
of the bulk of mammary tumor cells with that of CSC-enriched serial sphere 
passages of the same tumor cells, a gene signature associated with mammary 
CSC can be obtained, and potential CSC-specific oncoantigens identified 
(Cavallo et al., in preparation). We expect that vaccines targeting these CSC-
specific oncoantigens will result in a more effective control of clinically 
evident cancer, recurrences and metastases as compared to vaccines against 
oncoantigens of the differentiated tumor cell population, whose protective 
potential is mostly restricted to tumor prevention[33,35,64]. The two kinds of 
vaccine, against oncoantigens of CSC and of differentiated tumor cells, might 
have a synergic therapeutic effect.  
 
miRNAs 
While several protein-coding genes involved in malignancy have been 
identified and characterized, less is known for non-coding-genes, such as 
microRNAs (miRNAs). Nevertheless, miRNA can be of help in understanding 
the biology of the different mammary cancer subtypes and in identifying 
novel oncoantigens. Because of their ability to bind to many target mRNA, 
once their expression is altered, disease could occur through the deregulation 
of their target gene networks, particularly those leading to cancer. Moreover, 
miRNA appear to be involved in the maintenance of the CSC phenotype, by 
connecting stemness and metastasis through regulation of epithelial-to-
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mesenchymal transition [65]. The identification of down-regulated miRNA in 
differentiated tumor cells or in CSC can thus lead to identification of their 
target genes as potential oncoantigens. Even if the possibility to effectively 
target in vivo tumor over-expressed miRNA existed, they could hardly be 
considered a new class of oncoantigens, because they are not immunogenic. 
Nevertheless tumor-derived, over-expressed miRNAs can be secreted outside 
of the cell and can be detected in the sera, thus representing a new class of 
diagnostic and prognostic biomarkers [66]. Their titration can be used to 
assess disease progression and the effectiveness of vaccination against 
oncoantigens. 
Global miRNA deregulation has been shown in breast cancer [67-70] 
while specific miRNAs have been associated with clinico-pathological 
features of breast tumors such as estrogen and progesterone receptor 
expression [71], tumor grade [68], vascular invasion or proliferation index 
[72]. Profiling studies have been mainly focused on miRNAs deregulated in 
primary breast cancer [70,73] or in breast cancer cell lines [74], while 
characterization of a deregulated miRNA expression profile in different 
tumor stages would permit to assess miRNA involvement in tumor 
progression. Using this type of approach, we have recently characterized the 
deregulated miRNA expression profile during tumor progression in 
mammary cancer-prone HER-2 transgenic mice. The miRNAs found down 
regulated during tumor progression and their putative targets are under 
investigation. miR-135a and miR-135b were found to be up-regulated during 
tumor progression [75]. While their involvement in breast cancer has never 
been described, by exploiting data on the expression of miRNAs in human 
breast cancers [70,73], the over-expression of miR-135b, but not miR-135a, 
appeared to be associated with poor prognosis. In addition, miR-135b over-
expression in basal-like and estrogen-negative human tumor shown by this 
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meta analysis fits in well with the notion that mammary tumors of our HER-2 
trasngenic mice are similar to basal-like and estrogen-negative human 
mammary carcinomas [76]. Down-modulation of miR-135b in cancer cells 
from HER-2 transgenic mice revealed its major role in anchorage-independent 
growth and lung metastasis formation. MID1 and MTCH2 were identified 
and validated as putative miR-135b targets.  
 
Vaccines and adjuvants 
The efficacy of a vaccine rests on its ability to induce an effective 
antibody and cell-mediated immune response against the target antigen. Once 
triggered, immunity is kept at an efficacious protective intensity during the 
aging of the individual, both through natural re-stimulation or vaccine boosts. 
Two are the components of a vaccine: the antigen and the adjuvant(s). The 
first one is obviously necessary to direct the induced immune response 
against the right target, while the second is any substance able to promote 
antigen recognition and the establishment of the immune memory. Different 
sources of antigen have been tested. When the antigen source is complex - as 
in the case of live, irradiated or genetically modified tumor cells, dendritic 
cells, recombinant viral/bacterial vectors or naked DNA - it normally displays 
some intrinsic adjuvant activities, while the use of purified proteins or 
peptides always requires the addition of extrinsic adjuvants. Each vaccine 
preparation can be given as adjuvanted standalone intervention or combined 
with cytokines or other immune-modulatory factors to optimize immune 
system activation. 
 
Proteins and peptides 
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Protein- and peptide-based antigen vaccines were among the first 
defined vaccines demonstrating both protective and therapeutic efficacy in 
animal models [40,77]. Many late-stage clinical trials assessing the efficacy of 
protein- and peptide-based vaccines have been performed or are currently on 
going; however, only a few of them have reported consistent rates of 
objective, long-term clinical responses [78].  
Proteins usually contain several MHC restricted epitopes recognized 
by both cytotoxic and helper T cells, and linear or conformational epitopes 
that can be recognized by antibodies. Protein vaccines can thus induce a 
complete adaptive immune response, when taken up and processed by 
antigen-presenting cells (APCs), but have several demerits in terms of 
manufacturing and safety controls. To avoid these drawbacks, and as a 
consequence of the rampant T-cell chauvinisms of the nineties, short synthetic 
epitopes expected to directly bindMHC molecules, and hence be presented to 
T cells, have been widely used. The peptides are generally emulsified with 
Montanide ISA51, a clinical grade of Freund’s incomplete adjuvant, prior to 
administration, or directly pulsed on antigen presenting cells to be used for 
vaccination [77].  
The earlier generations of peptide vaccines, aimed at inducing a 
cytotoxic T cell response, were composed of one to several MHC class I-
restricted peptides of a single MHC-type. Various types of new generation 
peptide-based vaccines have since been developed. To stimulate both 
cytotoxic and helper T cell responses, MHC class I- and MHC class II-
restricted peptides have been formulated independently and administered at 
a separate site to the same patients. Alternatively, multi-peptide cocktails 
have been used. Synthetic long peptides likely to contain both MHC class I 
and class II epitopes suitable for presentation on several MHC haplotypes 
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have also been generated. These multi-epitope vaccines can thus be used in a 
wide range of patients [77]. Most of single- or multi-epitope vaccines are 
based on the native peptide sequences, with or without modification of the 
anchor amino acid residues. Some of the latest generation of vaccines 
however are based on hybrid peptide sequences derived by fusion of peptides 
from different molecules. The Ii-Key/HER2/neu (776–790) peptide vaccine is 
an example of hybrid peptide obtained by fusing the Ii-Key 4-mer peptide 
and the human HER-2 (776–790) helper epitope. The Ii-Key peptide is the 
shortest active sequence of the Ii protein that catalyses direct charging of 
MHC class II epitopes to the peptide-binding groove, circumventing the need 
for intracellular epitope processing. The Ii-Key/HER2/neu (776–790) hybrid 
peptide vaccine induces significantly higher antitumor responses as 
compared with the native HER2/neu (776–790) peptide, even in the absence of 
an adjuvant [79]. Finally, an attempt has been recently made to generate 
personalized peptide vaccines, taking into account the pre-existing immunity 
of patients. Appropriate peptides for vaccination are screened and selected 
from a panel of vaccine candidates, based on MHC-haplotypes and detection 
of cytotoxic T cell precursors and IgG in the peripheral blood of each patient 
before vaccination. 
The majority of on going phase I-III clinical trials assessing the safety 
and efficacy of recombinant peptides in breast carcinoma patients is based on 
the administration of HER2-derived peptides, either as adjuvanted standalone 
interventions or combined with additional immunostimulatory agents [78].  
 
Cell vaccines 
24 
 
In principle, cell vaccines expressing a given antigen already contain all 
the constituents of a good vaccine, with cells themselves acting as complex 
adjuvants through many activities related also to immunogenic death. In 
addition to the known target antigen, tumor cells can express many other 
unknown tumor antigens, resulting in the simultaneous induction of immune 
responses against a constellation of targets expressed in the tumor. In practice, 
unmodified tumor cells rarely make good vaccines because on the one side 
their antigenicity was dampened by immune editing during tumor 
development, on the other side the immune system is poorly responsive 
because of immune tolerance and tumor-induced immune suppression. 
A major problem in the field of preclinical cancer vaccines is the lack of 
studies comparing different vaccine designs and vaccination protocols under 
identical experimental conditions. Fortunately the development of 
genetically-modified cell vaccines in the 1990s coincided with widespread use 
of TS/A mouse mammary carcinoma cells as recipients, spearheaded by 
Guido Forni and co-workers, leading to the establishment of an informal 
network of researchers that produced a large corpus of comparable 
experiments[80-82]. The results contributed a considerable understanding to 
the use of cytokine genes and other immune-related molecules as biological 
adjuvants, and led to the definition of a small number of genes showing a 
definite potential in the development of anti-cancer vaccines[82]. These 
studies provided also evidence of the destructive potential of forced 
expression of immune-related molecules in tumor cells, which in various 
instances led to increased tumor or metastasis growth, or to unexpected 
unwanted effects on the host. 
The experience accumulated with earlier gene-modified cell vaccines 
provided the bases for the development in the following decade of the Triplex 
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cell vaccine. To fight the aggressive mammary carcinogenesis driven by the 
activated HER-2 oncogene we designed a cell vaccine combining three 
powerful immune stimuli, the HER-2 gene product p185 and two biological 
adjuvants, interleukin 12 (IL-12), the major cytokine of antigen presentation, 
and allogeneic class I major histocompatibility complex antigens, which 
activate many T cell clones. The first Triplex formulation was based on 
vaccinations with HER-2+, MHC-allogeneic mammary carcinoma cells 
followed by the administration of recombinant IL-12[15]. To avoid systemic 
administration of the cytokine we then transduced vaccine cells with IL-12 
genes, thus obtaining a single-component cell vaccine[83]. The results 
obtained with either formulation were similar. 
The Triplex vaccine, when administered to young HER-2 transgenic 
mice was able to block indefinitely mammary carcinogenesis at the stage of 
atypical hyperplasia, preventing the development of mammary carcinomas 
and resulting in 100% survival at one year or more of age, when all non-
vaccinated mice had already succumbed to tumors[15].  
The key elements of the complete protection afforded by the Triplex 
vaccine were defined through a large series of protocol variations, which were 
explored not only in vivo, butalso using a combination of in silico and in vivo 
approaches[84]. 
1. The Triplex was the minimal combination yielding long-term 
protection, all subsets of just one or two components significantly 
prolonged tumor latency, but did not prevent tumor development. 
2. To be effective, vaccination had to start early in life, before the onset 
of malignant tumors. 
3. Periodic vaccination boosts were required throughout the life of the 
mouse to maintain protective immunity, in a situation remindful of 
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tetanus vaccination in humans, i.e. the vaccine elicited long-lasting, 
but not lifetime immunity. 
 
DNA vaccines 
DNA vaccines are simple circles of DNA carrying the sequence coding 
for the target antigen that once enter mammalian cells result in antigen 
synthesis, processing and presentation in the MHC-context with induction of 
both cell- and antibody-mediated immune responses. Their ability to 
determine a relatively low but persistent in vivo antigen expression may be 
particularly effective in inducing B-cell affinity maturation. DNA vaccines are 
stable, relatively inexpensive, have an easy good manufacturing practice 
production, lack anti-vector immunity, and are extremely versatile. The 
antigen sequence can be in its native form or modified, alone or together with 
sequences coding for immune modulators or molecules influencing antigen 
processing and presentation. They are effective even when administrated 
without adjuvants, as they carry intrinsic danger signals. Unlike mammalian 
DNA, plasmids are rich in unmethylated CpG dinucleotides that warn of 
bacterial infection and activate the innate immune response via Toll-like 
receptor 9 expressed on APCs. DNA vaccines are commonly delivered 
intradermal or intra-muscularly by simple injection or through bio-ballistic 
methods or in vivo electroporation [34]. The latter is one of the most 
promising current technologies for DNA vaccine delivery [85], that greatly 
impacts vaccine immunogenicity and efficacy by increasing antigen delivery 
up to a 1000 fold over naked DNA delivery alone, with improved in vivo 
immune response magnitude. Recently, a new strategy based on microneedles 
implantation into the skin of biodegradable polymer films containing DNA 
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polyplexes and adjuvant molecules, has been tested with promising results 
[86]. 
DNA vaccines directed against HER-2 have proven to be successful in 
the prevention of tumor growth in transplantable tumor models as well as in 
HER-2 transgenic mice [16,34,36,40].  
In HER-2 transgenic mice DNA vaccines based on plasmids coding for 
the extracellular and transmembrane domain of rat HER-2 (RRT plasmids) 
effectively and persistently hamper the expansion of incipient tumors. This 
remarkable protection was correlated with the induction of anti-HER2 
antibodies [16]. RRT plasmids efficacy fades away when they are 
administered to mice bearing advanced tumors[33,35,64]. A significant 
therapeutic effect was obtained only when RRT vaccination was associated 
with T regulatory cells depletion [17], which, however, could also increase the 
risk of autoimmunity [87]. To obtain a stronger immune response and 
circumvent natural tolerance two new chimeric DNA vaccines (RHuT and 
HuRT) were constructed, encoding HER-2 extracellular and transmembrane 
domains composed in part by rat and by human sequences. RHuT encodes a 
protein in which the 410 NH2-terminal residues are from the rat HER2 and the 
remaining residues from human HER-2, while HuRT encodes a protein the 
first 390 NH2-terminal residues of which are from the human HER-2 and the 
remaining part from the rat HER-2. These chimeric plasmids combine the 
specificity, ensured by homologous portions, and tolerance break, ensured by 
heterologous portions [36]. We found that this combination effectively primes 
immune effector cells in tolerant hosts [34,36].  In principle, this strategy of 
combining heterologous with self moieties can be applied to any oncoantigen 
that share high level of sequence identity and T cell epitopes to produce a 
potent DNA vaccine. 
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A new kind of anti-HER-2 DNA vaccine has recently been developed 
as part of a strategy aimed at subverting the tumor-induced 
immunosuppressive circuits that weaken the vaccine induced antitumor 
response. Most of these circuits are based on abnormal differentiation of 
APCs which results in decreased production of fully competent APCs and 
accumulation of immature tolerogenic dendritic cells [88]. This new DNA 
vaccination strategy combines antigen expression with the silencing of 
immunosuppressive molecules that are responsible for the tolerogenic 
behavior of APCs. This double action is associated with two distinct modules; 
one is the conventional antigen expression cassette, while the other generates 
short interfering (si)RNAs directed against negative immune regulators, such 
as IDO or IL-10 [89]. This second module is expected to ensure optimal 
presentation of the encoded antigen by APCs. 
 
DNA vs cell vaccines 
Different vaccination technologies are only rarely compared head-to-
head[90].We have developed highly active cell and DNA vaccines against 
HER-2 in the same model systems[15,16], and we have also taken the 
opportunity to perform direct comparisons in the prevention of tumor 
development in transgenic mice[37]. The fundamental result was that both 
cell and DNA vaccines are equally effective in protecting mice from tumor 
onset. A preference for DNA vaccines, however, is based on various 
distinctive features, in particular for what concerns translational value. For 
example, in our model systems, DNA vaccines required fewer boosts than cell 
vaccines to maintain long-term protection, furthermore DNA vaccines, being 
molecularly defined and cell-free, are more suitable for human use. Finally, in 
the perspective of making vaccines for novel oncoantigens, it is certainly 
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easier to produce and test a panel of new DNA vaccines than a corresponding 
cell vaccine endowed with appropriate immunogenicity.  
 
Prime and boost strategies 
The successes achieved in vaccination against infectious diseases were 
the driving force for the generation of anti-cancer vaccines and are still a 
source of information and ideas for improving the effectiveness of anti-tumor 
vaccination.  
In keeping with the well-known tenet of infective vaccinology that 
boosting injections are critical for protection, homologous booster 
immunizations that utilize re-administration of the same vaccine formulation 
have essentially been used since the initial development of anti-cancer 
vaccines. An effective vaccine usually requires more than a one-time 
immunization in the form of a prime-boost. For example, when RRT 
vaccinations of HER-2 transgenic mice bearing incipient tumors was repeated 
at 10-week intervals, most of one-year-old mice were still free of palpable 
tumors [16,36], greatly improving the results of a single cycle of RRT 
vaccinations.  
However the homologous prime-boost approach is not feasible for 
some types of vaccines like viral vector-based ones, because the immune 
response induced by the earlier immunization can rapidly clear the vector in 
subsequent boost immunizations. In these cases prime-boost immunizations 
have been given with unmatched vaccine delivery methods while using the 
same antigens, in a heterologous prime-boost format. It is now widely 
accepted that these heterologous prime-boosts are more immunogenic than 
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homologous prime-boosts in vaccination against both infectious diseases [91] 
and cancer [92].  
A well-designed heterologous prime-boost approach can expand the 
scope of immune responses and improve the effectiveness of existing 
vaccines. The heterologous prime–boost can take various forms; the length of 
time separating the primary and the following immunizations and the order 
of prime–boost administrations may be important, although antigen-
dependent. In HER-2 transgenic mice priming with RRT plasmids and 
subsequent boosting with allogeneic (H-2q) mammary cancer cells expressing 
rat HER-2 and engineered to release interferon (IFN)-γ were able to arrest 
mammary tumor progression [38]. The sequential administration of DNA 
plasmid and an adenoviral vector against HER-2 in different combinations 
resulted in higher frequencies of antigen-specific antibodies and activated T 
cells, and higher degree of protection from tumor development than do DNA 
or recombinant viral vectors alone [93,94].  
 
Vaccines and chemosensitivity 
The therapeutic efficacy of vaccination for any human tumor remains 
controversial because the outcomes from clinical trials are far inferior to that 
anticipated. The reasons of this general clinical failure of cancer vaccines are 
still to be elucidated, but the general finding is that vaccines are able to induce 
an anti-tumor immune response but this is too inefficient to keep pace with 
rapidly growing, mutating tumors in situ. 
The clinical insufficiency of cancer vaccines encourages the 
examination of synergy between vaccination and other therapies and with 
chemotherapy in particular. Indeed, certain chemotherapeutic agents have 
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shown immunomodulatory activities, and several combined approaches have 
been attempted [95]. For instance, chemotherapy has been proven to enhance 
the efficacy of tumor cell vaccines by favoring tumor cell death and thus 
enhancing tumor-antigen cross-presentation in vivo. Drug induced 
lymphodepletion may induce the production of cytokines favoring 
homeostatic proliferation, and/or ablate immunosuppression mechanisms. 
Furthermore, monoclonal antibodies can synergize with chemotherapy by 
inducing endogenous tumor-specific humoral and cellular immune responses. 
Moreover, it has been reported that vaccinated patients receiving subsequent 
chemotherapy exhibited significantly delayed tumor progression and longer 
survival relative to those receiving vaccinations without subsequent 
chemotherapy or those receiving chemotherapy alone. Improved clinical 
outcome appeared dependent on the specific combination of therapeutic 
vaccination followed by chemotherapy [95,96]. 
In pre-clinical models we have recently reported that vaccination 
against antigens expressed by vascular cells can sensitize clinically evident 
mammary carcinomas to a subsequent chemotherapy treatment [97]. DNA 
vaccination targeting angiomotin, one of the angiostatin receptors expressed 
by endothelial cells of angiogenic tissues [98], induced an antibody response 
that alters the structure and the permeability of tumor vessels, resulting in 
vessel maturation and stabilization. These antibody-induced vessel alteration 
was effective both in halting the progression of clinically evident tumors and 
in making them more susceptible to chemotherapy, thanks to an enhanced 
tumor perfusion [97]. A similar effect was found in patients treated with a 
humanized monoclonal antibody neutralizing vascular endothelial growth 
factor (bevacizumab) [99,100].  
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Expert Commentary 
The enormous amount of successful pre-clinical applications of cancer 
vaccines has not met a corresponding efficacy when translated into clinic. This 
fact is not limited to breast cancer, but is a generalized result [101]. These 
frustratingly slow progresses of anti-cancer vaccination are due to various 
weaknesses of the pre-clinical testing, such as the target antigen choice (not 
always the target was an oncoantigen) and the inadequacy of available animal 
models of human cancer [89]. Genetically engineered mouse models have 
significantly contributed to our understanding of cancer biology and 
treatment[18]. They have certainly proven to be better clinical models as 
compared to “instant cancers” obtained by injecting mice with transplantable 
tumors, or by bombarding mice with carcinogen doses higher than those that 
any human will ever encounter[102]. However, they still have significant 
limitations in modeling human cancer that the recently developed mice with a 
reconstituted immune system are not expected to easily solve. If we are going 
to beat cancer, we need a new path to progress [102]. 
Naturally occurring pet tumors provide meaningful systems to study 
the complexity of human tumors in a far less artificial way. Using naturally 
occurring cancer in pet animals could also solve the ethical issues of animal 
experimentation. While medical research involving animals is sometimes 
controversial and misunderstood, experimentation in pets with naturally 
occurring cancer will provide benefits for both man and animals.  
The use of pets in translational oncology can hugely accelerate vaccine 
development for many reasons. When effectiveness of a cancer vaccine has 
been proven in mice, researchers should move to veterinary trials in pet 
animals. Whereas there are strict regulations concerning treatments to be used 
and commercialized for veterinary use, as well as for clinical trials in humans, 
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there are fewer regulations for phase I/II/III clinical trials before drug use in 
pets; rather, it is left to the discretion of the owner [103]. Because most pet 
cancer diagnoses end in death, owners are often eager to enroll their animals 
in clinical trials that could save their pet’s life, and possibly provide the 
necessary evidence to move a promising vaccine to human clinical trials. 
Compared with humans, pets have compressed life spans, so the efficacy of a 
vaccine in improving survival can be determined relatively quickly [44]. 
In conclusion, we believe that part of the failures of cancer vaccines in 
humans can be ascribed to the use of unfaithful preclinical models or, more 
precisely, to the use of models that were inappropriate for the preclinical 
development of cancer vaccines. The advent of genetically modified mice 
expressing human oncoantigens, and the possibility to move from 
experiments in mice to trials in cats and dogs provides a realistic preclinical 
framework for the development of vaccines against mammary carcinoma 
endowed with true translational potential. 
 
Five year view 
Until now HER-2 has dominated the scene of preclinical vaccine 
research in mammary carcinoma, not only because it is an excellent 
oncoantigen, but also because of the lack of promising antigenic targets in 
HER-2-negative tumors. Search strategies discussed here will lead to the 
discovery of oncoantigens in triple-negative and other subtypes lacking HER-
2 amplification, resulting in the preclinical testing of novel vaccines against 
mammary carcinomas. 
For what concerns the future of anti-HER-2 vaccines, the discovery in 
human tumors of activated HER-2 variants, such as p95 and Delta16, and the 
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role of HER-2 in cancer-initiating cells and in the early stages of mammary 
carcinoma development will refocus the attention of vaccine research from the 
bulk of tumor cells expressing full length HER-2 to more rare cell populations 
and molecular variants, possibly representing more significant targets for 
therapeutic vaccines against mammary carcinoma. 
Finally, all preclinical research has shown that anti-HER-2 vaccines can 
induce therapeutic responses in the adjuvant setting, and the clinical 
experience with trastuzumab demonstrates that anti-HER-2 antibodies are 
effective against human breast cancer. Many vaccine trials are ongoing and 
others will start in the near future. We expect positive clinical results. 
 
Key Issues 
•  There is no approved vaccine for human breast cancer, despite decades of 
research. Early mouse models of mammary carcinoma, which do not 
mirror the immunology of human breast cancer, hampered the 
development of effective vaccines. 
• The advent of HER-2 transgenic mice fostered the design of a novel 
generation of powerful anti-HER-2 vaccines, and led to the development 
of novel concepts in tumor immunity 
• Different vaccine technologies, designs and protocols yielded excellent 
protection from HER-2-positive mammary carcinoma in mice. DNA 
vaccinationemerged as an eminently flexible and translatable technology.  
• Highly immunodeficient mice reconstituted with a human immune 
system can be used to test vaccines against human tumors, however 
current models do not reconstitute the complexity of human tumor 
immunology. 
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• Oncoantigens are defined as tumor antigens causally involved in tumor 
onset and malignancy. Oncoantigens are optimal vaccine targets for the 
prevention of tumor onset and metastasis development. 
• HER-2 is the prototypical oncoantigen of mammary carcinoma. The 
definition of search strategies combining preclinical and clinical systems 
areleading to the discovery of oncoantigens in mammary carcinomas 
lacking HER-2 overexpression. 
• Activated HER-2 isoforms expressed in human breast cancer are a 
promising target for the development of novel vaccines. 
• Preclinical development of innovative vaccines will find an optimal 
environment in novel genetically modified mice and in veterinary trials in 
companion animals. 
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